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Background: The correlation between efﬁcacy end points in randomized controlled trials (RCTs) of systemic therapy
for non-Hodgkin’s lymphoma (NHL) was investigated to identify an appropriate surrogate end point for overall survival
(OS).
Methods: RCTs of previously untreated NHL published from 1990 to 2009 were identiﬁed. Associations between
absolute differences in efﬁcacy end points were determined using nonparametric Spearman’s rank correlation
coefﬁcients (rs).
Results: Thirty-eight RCTs representing 85 treatment arms for aggressive NHL and 20 RCTs representing 42 arms
for indolent NHL were included. For aggressive NHL, differences in 3-year progression-free survival (PFS)/event-free
survival (EFS) were high correlated with differences in 5-year OS {rs of 0.90 [95% conﬁdence interval (CI) 0.73–0.96]}
and linear regression determined that a 10% improvement in 3-year EFS or PFS would predict for a 7% 6 1%
improvement in 5-year OS. For indolent histology disease, differences in complete response were strongly correlated
with differences in 3-year EFS [rs 0.86 (95% CI 0.35–0.97)], but there was no correlation between 3-year time-to-event
end points and 5-year OS.
Conclusions: Improvements in 3-year EFS/PFS are highly correlated with improvements in 5-year OS in aggressive
NHL and should be explored as a candidate surrogate end point. Deﬁnition of these relationships may inform future
clinical trial design and interpretation of interim trial data.
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introduction
Selection of efﬁcacy end points for randomized controlled trials
(RCTs) of non-Hodgkin’s lymphoma (NHL) depends largely
on histology and treatment goals. In untreated aggressive
histology lymphomas, primary treatment with chemotherapy is
undertaken with curative intent, so the development of new
treatments to increase the rate of overall survival (OS) remains
an important goal for this patient population. In contrast,
indolent histology lymphomas have a very long natural history
and are generally incurable, and systemic treatment is generally
directed at improving symptoms and prolonging progression-
free survival (PFS).
Although OS is an unambiguous measure of efﬁcacy in
clinical trials, its use as a primary end point requires a long
duration of follow-up and may prolong the process of
identifying novel and potentially beneﬁcial therapy. Surrogate
end points for OS have been explored in breast [1, 2], lung [3],
and rectal cancers [4] but only have been validated in colon
cancer [5–7]. Nonetheless, there is emerging acceptance of such
end points by the oncology community and by regulatory
agencies [8–10].
While there is great interest in developing validated surrogate
end points for OS, there is no consensus on the necessary
validation process [5,11–14]. Prentice et al. proposed that the
surrogate marker should correlate with the true end point and
capture the net effect of the treatment on the true end point
[11, 12]. More recently, Buyse et al. [13] stated that the
surrogate should be predictive of the ﬁnal end point using both
trial- and individual-level data. Additionally, Begg and Leung
[14] argued that signiﬁcant differences observed for the
candidate surrogate end point in trials should be concordant
with results for the true end point.
Surrogate end points have yet to be explored in the trials of
NHL. Time-to-event end points including event-free survival
(EFS) or PFS permit earlier reporting of results, but their ability
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describe reporting of primary and secondary end points in
RCTs of NHL and to determine the correlations between
response, intermediate time-to-event, and survival end points
in the treatment of NHL with the goal of identifying a surrogate
end point for OS.
methods
trial selection
RCTs were eligible for inclusion if they enrolled previously untreated
aggressiveNHLwithatleast100patientsperarmoruntreatedindolentNHL
with at least 75 patients per arm. Studies were excluded if they primarily
investigated the effect of autologous stem-cell transplantation (ASCT),
maintenance, or local therapies (i.e. surgery, radiation); exclusively enrolled
T cell, mantle cell, HIV-associated Burkitt, primary central nervous system,
or small-cell lymphocytic lymphomas (including chronic lymphocytic
leukemia); and those reporting pooled data from multiple trials.
literature search. A systematic literature search was conducted to identify
RCTs using Medline, EMBASE (Exerpta Medica Database), and the
Cochrane Central Register of Controlled Trials databases from 1 January
1990 to 1 May 2009. Search strategy included MeSH headings and keywords
such as ‘Lymphoma, Non-Hodgkin’s’, ‘non-Hodgkin’ or ‘NHL’;
‘Antineoplastic Agents’, ‘Antineoplastic Combined Chemotherapy
Protocols’or ‘chemotherapy’; and‘RandomizedControlled ClinicalTrial’ or
‘Phase III Clinical Trial’. A manual search was also carried out for abstracts
in the published proceedings of the annual meetings of the American Society
of Clinical Oncology, American Society of Hematology, and the triennial
International Conference on Malignant Lymphoma in Lugano from 2004 to
2009. Abstracts from all identiﬁed RCTs were manually reviewed for
eligibility based on inclusion and exclusion criteria. RCTs were subgrouped
for analysis by disease histology (i.e. aggressive or indolent).
data collection. For each eligible published RCT, data were extracted
regarding study design, sample size, enrollment dates, experimental arms,
and response rates (RRs). The standard chemotherapy arm and primary
end point in each trial were determined by consensus of two investigators
(LL and MC). Data on EFS, PFS, and OS were determined for all treatment
arms using published data or survival curves. Reported time-to-event end
points reﬂect the original terminology used by authors in the RCT. For our
analysis, time-to-event end points were deﬁned as PFS or EFS according to
established (i.e. per-protocol) deﬁnitions in the International Working
Group Revised Response Criteria for Lymphoma [15]. Results of each trial
for PFS, EFS or OS were considered signiﬁcant based on the per-protocol
analysis with a P-value £ 0.05. RCTs were categorized as ‘positive’ if the
speciﬁed primary end point was met. If a RCT was reported on multiple
occasions, data were collated from all abstracts and the most recent data
were used in the event of discrepancies.
statistical analysis
Descriptive statistics were used to summarize trial characteristics and end
point selection. To evaluate changes in primary end point selection over
time, studies were dichotomized into an earlier or later time period based
on the year of study initiation and the frequency of time-to-event end
points was examined using the Cochran–Armitage test for trend. In
addition, trials were evaluated based on whether rituximab was included in
at least one of the treatment arms, and differences in primary end point
selection were determined using Fisher’s exact test. For each trial, the
absolute differences in end points [complete response (CR), EFS, PFS, and
OS] were calculated as the estimate in the experimental arm minus the
estimate in the standard arm. For multiarm and factorial-design studies,
only one randomly chosen experimental arm (or factorial group) was used
to ensure that the absolute differences of the same end point were
considered independent.
The nonparametric Spearman’s rank correlation coefﬁcient (rs) was used
as a measure of correlation between the differences in (i) CR and
intermediate time-to-event end points (3-year EFS/PFS or OS) and (ii)
potential surrogate end points (CR, 3 year EFS/PFS) and 5-year OS. In this
analysis, PFS and EFS were considered together as an intermediate time-to-
event end point since the per-protocol deﬁnition of EFS always included
progression and death as events; however, a separate analysis was also
presented where possible. Correlation coefﬁcients were compared using the
normal approximation to the z-transformation of rs and its standard
deviation. For strongly correlated end points, linear regression analysis was
carried out to obtain slope, which served as a conversion factor between end
points and determined the proportion of variability explained (R
2).
Furthermore, concordance of strongly correlated end points was assessed by
determining the proportion of trials in which the set of end points led to
the same conclusion based on statistical signiﬁcance testing (P < 0.05).
results
A total of 58 RCTs conducted from 1978 to 2005 were
identiﬁed: 38 in aggressive histology and 20 in indolent
histology lymphomas (Table 1). The aggressive lymphoma
RCTs included 85 treatment arms representing 16 103 patients
and had a median follow-up of 55 months (range 20–108). The
indolent lymphoma RCTs included 42 treatment arms and
5128 patients, with a median follow-up of 52 months (range
29–144).
end point selection and reporting
Regardless of lymphoma histology, almost all trials reported OS
(94% for aggressive, 95% for indolent), most trials included RR
(97% for aggressive, 75% for indolent), but only approximately
one-third of the trials reported at least one other time-to-event
end point (Table 1).
Seven different primary end points were reported, reﬂecting
heterogeneity in reporting terminology (Table 2). OS and RR
were unambiguously deﬁned as demonstrated by their
consistent frequency of use as primary end points regardless of
reported or per-protocol deﬁnitions for both histologies of
lymphoma (Table 2). Discrepancies between reported and per-
protocol end point deﬁnitions arose from the use of ‘event’ or
‘failure’, which affected time-to-event end points, such as PFS,
EFS, time-to-failure (TTF), failure-free survival (FFS), and
disease-free survival. For example if failure was deﬁned as
progression or death, FFS would be classiﬁed as PFS by the per-
protocol deﬁnition, whereas inclusion nonprogression events
suggested that this term was being used synonymously with
EFS.
For aggressive lymphoma RCTs, the most commonly
reported primary end point was OS followed by EFS. For
indolent lymphoma RCTs, choice of primary end point was
more heterogeneous, but use of either TTF or RR was most
common (Table 2). Trend in the selection of primary end
points was evaluated by comparing RCTs initiated before 1990
to those initiated following 1991 (Figure 1A) and by comparing
RCTs based on the presence of rituximab in at least one
treatment arm (Figure 1B). In the more recent time period, use
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and aggressive NHL trials (81% versus 36%, P = 0.006). In the
latter histologic subgroup, use of EFS became more common
(0% versus 36%, P = 0.007). In aggressive NHL, RCTs
evaluating rituximab were signiﬁcantly less likely to use OS as
the primary end point than RCTs without rituximab (14%
versus 64%, P = 0.013), but there was no such difference noted
for indolent histology NHL.
correlation between response and intermediate
time-to-event end points
For aggressive NHL, differences in CR rates strongly correlated
with differences in 3-year EFS/PFS with an rs of 0.70 [95%
conﬁdence interval (CI) 0.42–0.86] (Table 3). The rs between
differences in CR rate and differences in 3-year EFS and 3-year
PFS were 0.88 (95% CI 0.57–0.97) and 0.63 (95% CI 0.21–
0.84), respectively. There was a moderate correlation between
differences in CR rate and differences in 3-year OS with a rs of
0.58 (95% CI 0.29–0.77).
For indolent NHL, differences in CR rate also strongly correlated
with differences in 3-year EFS/PFS with a rs of 0.77 (95% CI 0.41–
0.92). While differences in CR rate correlated strongly with
differences in 3-year EFS when considered alone with a rs of 0.86
(95%CI0.35–0.97),therewasnocorrelationbetweendifferencesin
CR rate and differences in 3-year PFS or 3-year OS.
correlation between potential surrogate and OS
end points
There was no relationship between difference in CR and
difference in 5-year OS in either aggressive or indolent NHL
(Table 3). However, in aggressive NHL, differences in 3-year
PFS/EFS were highly correlated with differences in 5-year OS
with a rs of 0.90 (95% CI 0.73–0.96), and similarly strong
correlations were noted when differences in 3-year PFS and
3-year EFS were separately correlated with 5-year OS. In
contrast, there was no correlation between differences in these
intermediate time-to-event end points and differences in 5-year
OS in indolent NHL (Table 3).
In an exploratory analysis, we determined the correlation
between 3-year PFS or EFS with 5-year OS within individual
arms of the randomized trials (supplemental Data available at
Annals of Oncology online). Similarly, these two end points were
strongly correlated in aggressive NHL with a rs = 0.85 (95% CI
0.71–0.92, P < 0.001) (supplemental Figure S1, available at
Annals of Oncology online) but only moderately correlated in
indolent NHL with a rs = 0.56 (95% CI 0.2–0.78, P = 0.004)
(supplemental Figure S2, available at Annals of Oncology online).
linear regression analysis
For strongly correlated end points, linear regression was carried
out through the origin. In aggressive NHL, the regression of
differences in CR and 3-year EFS yielded a slope of 0.9 6 0.1
[61 standard error (SE) of the estimate] with a R
2 of 0.78
(Figure 2). The regression of differences in 3-year EFS/PFS and
5-year OS yielded a slope of 0.7 6 0.1 (61 SE of the estimate)
with a R
2 of 0.66 for aggressive histology NHL (Figure 3). In
indolent NHL, the regression of differences in CR and 3-year
EFS yielded a slope of 0.9 with a large SE (0.3) due to the
smaller number of trials.
These ﬁndings suggest that in aggressive NHL, a 10%
improvement in CR is estimated to correspond with a 9% 6
1% improvement in 3-year EFS and that a 10% improvement
in 3-year EFS or PFS would predict for a 7% 6 1%
improvement in 5-year OS. In indolent NHL, a 10%
improvement in CR is estimated to predict a 9% 6 3% beneﬁt
in 3-year EFS.
concordance of trial results for correlated end
points
For aggressive NHL, 26 trials had paired results where
differences in 3-year EFS/PFS and 5-year OS between treatment
Table 1. Characteristics of included phase III trials
Characteristic Aggressive
histology
(N = 38), n (%)
Indolent
histology
(N = 20), n (%)
Sample size
Median 382 244
Range 177–1222 131–428
Time period of study
Before 1990 16 (42) 7 (35)
1991–2005 22 (58) 13 (65)
Accrual duration (years)
Median 4 5
Range 1–10 2–9
Follow-up duration (months)
Median 55 53
Range 20–108 29–144
Design
Two-arm 25 (66) 12 (60)
Three-arm 1 (3) 2 (10)
Four-arm 1 (3) 0
Two-arm, Two-stage 5 (13) 6 (30)
2 · 2 factorial 6 (16) 0
Number of comparisons per trial
1 33 (87) 18 (90)
2 2 (5) 2 (10)
3 3 (8) 0
Frequency of reported end point
a
OS 36 (94) 19 (95)
EFS 10 (26) 6 (30)
PFS 12 (32) 6 (30)
DFS/RFS 15 (39) 4 (20)
FFS 8 (21) 2 (10)
TTF 4 (10) 10 (50)
TTP 2 (5) 4 (20)
RR 37 (97) 15 (75)
Outcomes
Positive 12 (32) 11 (55)
Negative 26 (68) 9 (45)
aIncludes primary and secondary end points, with percentages presented as
a ratio of total number of randomized clinical trials.
OS, overall survival; EFS, event-free survival; PFS, progression-free survival;
DFS, disease-free survival; RFS, relapse-free survival; FFS, failure-free
survival; TTF, time-to-failure; TTP, time-to-progression; RR, response rate.
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results were present in 23 trials (15 had no difference between
arms for either end points and 8 had signiﬁcant differences for
both end points, Table 4). The three discordant trials all
showed a signiﬁcant difference in the 3-year time-to-event end
point, but no difference in 5-year OS.
Of the 14 indolent lymphoma trials that had paired results
for CR and 3-year EFS/PFS, eight had concordant conclusions
(ﬁve reported statistically signiﬁcant differences for both end
points and two trials reported no difference at either end
points, Table 4). Among the six trials with discordant results,
ﬁve had no difference in CR but did have a signiﬁcant
difference in 3-year EFS/PFS, while only one trial had
a difference in CR but no difference in 3-year EFS/PFS.
discussion
Despite the lack of validated surrogate end points in NHL, our
review reveals that time-to-event end points are increasingly
used in place of OS as the primary end point in recent phase III
clinical trials. There was a trend toward increasing use of EFS
and TTF, respectively, in RCTs of aggressive and indolent
histology disease. Improvements in CR strongly predicted for
improvements in 3-year EFS in both aggressive and indolent
histology lymphomas but were not predictive of OS. In
aggressive histology lymphoma, 3-year PFS/EFS were strongly
correlated with 5-year OS, and statistically signiﬁcant
differences in PFS/EFS observed at 3 years predicted for
differences in OS after 5 years of follow-up. However,
considerable inconsistency exists both in the reporting and
deﬁnition of failure or event end points. Our results suggest
that 3-year PFS should be further explored as a candidate
surrogate end point in RCTs of aggressive NHL using
individual patient data.
A validated surrogate end point for 5-year OS offers potential
advantages for conducting clinical trials more efﬁciently and
expediting development of new treatments. In contrast to OS,
however, time-to-event end points are poorly deﬁned and may
suffer from bias in ascertainment [16–18]. For example EFS is
a composite end point consisting of objective measures, such as
death and progression, in addition to more subjective
components (i.e. investigator decision to initiate new
treatment). Guidelines for the harmonization of response
assessment in clinical trials of lymphoma provide a clear
deﬁnition and methodology for assessing progression but do
not address the deﬁnition and assessment of nonprogression
events [15, 19]. Consequently, PFS may be a better candidate
surrogate since the speciﬁcity of included ‘events’ has
implications for the power of a trial, the likelihood of
a signiﬁcant result, and ability to conduct cross-trial
comparisons [18].
Recognizing that the majority of RCTs were initiated before
the publication of guidelines to harmonize end points [15, 19],
PFS and EFS were combined in our analysis. For both
histologic subgroups of lymphoma, initial CR predicted for lack
of events at 3 years, but the correlation with OS at either 3 or 5
years was not strong, implying that attainment of CR does not
provide information about longer term outcomes. While CR
and 3-year EFS were strongly correlated, this may be partially
attributed to the actual deﬁnition of event, which encompassed
lack of response or absence of CR in some trials. In indolent
lymphoma, a similar relationship between higher CR rates and
improved EFS/PFS has been demonstrated in individual trials
of rituximab-based treatment [20–22] but was not consistently
seen in trials evaluating cytotoxic chemotherapy [23–25].
However, attainment of CR did not predict for improved OS,
which was likely due to the availability of effective treatments
for relapsed or refractory disease and the relatively short
duration of follow-up of 5 years, which may be inadequate for
evaluation of OS given the long natural history of indolent
lymphomas.
For aggressive NHL, the strong relationship between CR and
EFS/PFS is not surprising. Achievement of CR may be
associated with lower relapse rates [26] and failure to achieve
CR is an indication for high-dose chemotherapy and ASCT for
young ﬁt patients. The correlation between CR and OS was
moderate at 3 years but was not apparent at 5 years of follow-
up. This dissociation between CR and OS at 5 years may reﬂect
the cumulative impact of relapse over time [27, 28]. In contrast,
a signiﬁcant number of deaths within the ﬁrst 3 years are likely
Table 2. Frequency and reporting of primary end points in lymphoma randomized clinical trials
a
Primary end point Aggressive (N = 38) Indolent (N = 20)
Reported, n (%) Per-protocol, n (%) Reported, n (%) Per-protocol, n (%)
OS 21 (55) 21 (55) 2 (10) 2 (10)
EFS 8 (21) 12 (32) 2 (10) 5 (25)
PFS 0 0 3 (15) 5 (25)
DFS 0 1 (3) 0 0
FFS 4 (10) 0 0 0
TTF 1 (3) 0 5 (25) 0
RR 2 (5) 2 (5) 5 (25) 5 (25)
CR 2 (5) 2 (5) 3 (15) 3 (15)
aPrimary end point based at time of study initiation. ‘Reported’ refers to the original terminology used by study authors, whereas ‘per-protocol’ refers to
classiﬁcation of the end point according to International Working Group guidelines based on its deﬁnition within the protocol [15].
OS, overall survival; EFS, Event-Free Survival; PFS, Progression-Free Survival; DFS, Disease-Free Survival; FFS, Failure-Free Survival; TTF, Time-to-Failure;
RR, Response Rate; CR, Complete Response.
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or residual disease). Although these patients may be offered
ASCT, they tend to have worse outcomes [29], so the
potentially confounding effect of ASCT on 3-year survival is
minimal.
It is striking that a 3-year time-to-event end point such as
PFS may be predictive of 5-year OS in aggressive histology
lymphoma, considering the diversity of treatments investigated
in the trials that we evaluated. The correlation between PFS and
OS in aggressive but not indolent NHL is consistent with the
observation that the relationship between these two end points
is inﬂuenced by expected survival post-progression (SPP) time
[30]. A signiﬁcant difference in PFS is more likely to predict for
signiﬁcant OS difference in a disease with a shorter expected
SPP such as aggressive lymphoma where median survival
following relapse is 9 months [27] compared with follicular
Figure 1. Trends in selection of primary end points according to (A) time period and (B) presence or absence of rituximab in at least one treatment arm of
the trial. RR/CR, response rate or complete response; FFS, failure-free survival/TTF, time-to-failure; PFS, progression-free survival; EFS, event-free survival;
OS, overall survival.
original article Annals of Oncology
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Aggressive Indolent
Nonparametric Spearman
rank coefﬁcient
95% CI P-value Nonparametric Spearman
rank coefﬁcient
95% CI P-value
CR and 3-year time-to-event and OS end points
CR and 3-year EFS 0.88 0.57–0.97 0.0003 0.86 0.35 to 0.97 0.0059
CR and 3-year PFS 0.63 0.21–0.84 0.005 0.41 20.52 to 0.88 0.35
CR and 3-year PFS/EFS 0.70 0.42–0.86 <0.0001 0.77 0.41–0.92 0.0007
CR and 3-year OS 0.58 0.29–0.77 0.004 0.41 20.1 to 0.74 0.098
Potential surrogate end points and 5-year OS
CR and 5-year OS 0.50 0.23–0.74 0.01 0.21 20.34 to 0.5 0.44
3-year EFS or PFS and 5-year
OS
0.90 0.73–0.96 <0.0001 0.26 20.38 to 0.72 0.41
CI, conﬁdence interval; CR, complete response; EFS, Event-Free Survival; PFS, Progression-Free Survival; OS, overall survival.
Figure 2. Correlation between differences in complete response rates and differences in 3-year event-free survival in aggressive non-Hodgkin’s lymphoma.
Solid line represents the linear regression with 95% conﬁdence intervals indicated by the dashed lines.
Figure 3. Correlation between differences in 3-year event or progression-free survival and 5-year overall survival in aggressive non-Hodgkin’s lymphoma.
Solid line represents the linear regression with 95% conﬁdence intervals indicated by the dashed line.
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Treatment
a N Primary end point
(per-protocol)
Signiﬁcant
difference in CR
Signiﬁcant
difference in
EFS/PFS
Signiﬁcant
difference in OS
Superior
arm
Aggressive histology lymphoma
Dose-escalated CHOEP-21
versus CHOEP-21 [33]
389 EFS No No No No difference
R-CHOP-14 versus CHOP-
14 for 6 versus 8 cycles
[34]
1222 EFS Yes Yes Yes R-CHOP-14 for 6 cycles
CEOP-14 versus CEOP-21,
6R [35]
217 OS No n/a No No difference
Escalated R-CEOP versus
escalated CEOP [36]
204 DFS No n/a No No difference
Intensiﬁed CHOP-14 for 6
cycles versus standard
CHOP-21 for 8 cycles [37]
477 OS No No No No difference
Mini-COEP versus P-VEBEC
[38]
232 OS No No No No difference
R-CHOP versus CHOP, then
R-maintenance versus
nothing [39]
632 EFS n/a Yes No R-CHOP
R-CHOP-like versus
CHOP-like chemotherapy
[34]
824 EFS Yes Yes Yes R-CHOP like
PMitCEBO versus CHOP,
6GCSF [40]
784 EFS Yes No No No difference
Flexible versus ﬁxed dosing
of anthracycline in
ProMECE-CytaBOM or
ProMI-CytaBOM [41]
356 EFS No n/a No No difference
ProMECE-CytaBOM versus
ProMI-CytaBOM, then
maintenance
chemotherapy [42]
249 OS No No No No difference
R-CHOP-14 versus
CHOP-14 [43]
243 EFS n/a n/a Yes R-CHOP
CIOP versus CHOP [44] 211 OS Yes Yes Yes CHOP
Pirarubicin-COP versus
CHOP (2/3 dose) versus
pirarubicin-COPE [45]
443 OS No No No No difference
VEPA-B/FEPP-AB/M-FEPA
every 10 weeks for 3 cycles
versus VEPA-B/FEPP-B/
M-FEPA every 14 weeks
for 4 cycles [46]
447 OS No n/a No No difference
CHOP-14 versus CHOP-21,
6etoposide [47]
689 EFS n/a Yes No CHOP-14
ACVBP versus CHOP [26] 635 EFS No Yes Yes ACVBP
CHOEP versus CHOP, every
14 versus 21 days [48]
710 EFS n/a Yes No CHOEP
CNOP versus CHOP,
6GCSF [49]
458 EFS Yes Yes Yes CHOP
R-CHOP versus CHOP [50] 399 EFS Yes Yes Yes R-CHOP
CNOP versus CEOP [51] 249 OS No No No No difference
PMitCEBO versus
PAdriaCEBO [52]
473 OS No n/a Yes PMitCEBO
CHOP 1 IFN versus
CHOP [53]
435 RR No n/a No No difference
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Treatment
a N Primary end point
(per-protocol)
Signiﬁcant
difference in CR
Signiﬁcant
difference in
EFS/PFS
Signiﬁcant
difference in OS
Superior
arm
PACEBOM versus CHOP
[54]
459 OS No n/a No No difference
MACOP-B versus CHOP
[55]
374 OS No No No No difference
CAPOMEt versus CHOP-
MTX [56]
281 OS No n/a No No difference
MECOP-B versus MACOP-B
[57]
211 OS No n/a No No difference
Alternating B-CHOP-M and
PEEC-M versus B-CHOP-
M [58]
325 OS No n/a No No difference
CTVmP versus CVmP [59] 453 OS Yes Yes Yes CTVmP
MACOP-B over CHOP [60] 236 CR No Yes Yes MACOP-B
ProMACE-MOPP versus
MACOP-B [61]
221 OS No No No No difference
ProMECE-CytaBOM versus
MACOP-B [62]
210 OS No No No No difference
m-BACOD versus CHOP
versus ProMACE-
CytaBOM versus MACOP-
B [63]
899 OS No No No No difference
ProMACE-MOPP versus
CHVmP-VB [64]
430 OS n/a No No No difference
Escalated BACOP versus
BACOP [65]
238 OS No No No No difference
m-BACOD versus CHOP
[66]
325 OS No No No No difference
F-MACHOP versus
MACOP-B [67]
286 CR No n/a No No difference
Low-dose bleomycin
1 CHOP versus CHOP,
then low versus high-dose
MTX [68]
177 RR No No No No difference
Indolent histology lymphoma
R-CVP versus CVP [21] 321 EFS Yes Yes Yes R-CVP
R-CHVP 1 IFN versus
CHVP-IFN [22]
360 EFS Yes Yes No R-CHVP + IFN
R-MCP versus MCP [20] 358 RR Yes Yes Yes R-MCP
CID versus CD [69] 200 EFS No Yes No CID
MCP versus CHOP [25] 277 CR No n/a No No difference
F versus CVP [23] 381 PFS Yes No No No difference
FMD versus CMD [70] 400 PFS No n/a n/a CMD
R-CHOP versus CHOP [71] 428 EFS No Yes Yes R-CHOP
CHOP 1 bleomycin versus
cyclophosphamide [72]
228 OS No No No No difference
COPA 1 IFN versus COPA
[73]
291 PFS No Yes COPA + IFN
PmM versus COP, then
IFN-maintenance versus
observation [74]
246 RR Yes n/a n/a Not available
CHOP versus chlorambucil
1 prednisone [24]
259 RR n/a Yes No No difference
CHVP 1 IFN versus CHVP
[75]
242 PFS No Yes Yes CHVP + IFN
BOP versus COP [76] 164 CR No n/a No No difference
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of follow-up [31].
Our literature-based analysis is the ﬁrst to examine end
points in RCTs of untreated aggressive and indolent lymphoma
spanning a 25-year period. One previous meta-analysis of
follicular lymphoma trials reported a correlation between
higher CR rate and reduction in hazard rate for PFS [32].
However, that analysis included single-arm phase II trials and
effectively compared overall rates of CR and PFS associated
with individual treatment arms. By including only RCTs, we
were able to compare the actual impact of different treatments
on these end points.
This study does have some limitations. First, our analysis was
conducted using published trial-level data. To conﬁrm the
validity of 3-year PFS as a surrogate for 5-year OS in aggressive
lymphoma, it is necessary to assess their correlation using
individual patient data. Second, as the total number of trials
included for each histologic subgroup of lymphoma was small,
Table 4. (Continued)
Treatment
a N Primary end point
(per-protocol)
Signiﬁcant
difference in CR
Signiﬁcant
difference in
EFS/PFS
Signiﬁcant
difference in OS
Superior
arm
Cladribine versus CVP
versus cladribine + C [77]
197 PFS Yes Yes n/a Cladribine
FM versus mini-CHVdP [78] 155 CR Yes Yes No FM
FND versus alternating
triple therapy
(CHOD-bleomycin,
ESHAP, and NOPP) [79]
142 RR No Yes No No difference
CHVmP 1 IFN versus
F [80]
131 EFS No n/a n/a CHVP + IFN
b
CVP 1 IFN versus CVP,
then IFN-maintenance
versus observation [81]
155 RR n/a Yes No No difference
IFN versus prednimustine
versus observation [59]
193 OS No No No No difference
aBolded items represent the two comparator arms used for analysis in the following format: experimental versus standard arm.
bConclusion based on 2-year follow-up data.
RR, response rate; CR, complete response; EFS, Event-Free Survival; PFS, Progression-Free Survival; OS, overall survival; n/a, not applicable; CHOEP,
cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CEOP,
cyclophosphamide, epirubicin, vincristine, prednisone; R, rituximab; 14, cycle given every 14 days; 21, cycle given every 21 days; P-VEBEC, prednisone,
vinblastine, epirubicin, bleomycin, etoposide, cyclophosphamide; PMitCEBO, prednisolone, mitoxantrone, cyclophosphamide, etoposide, bleomycin,
vincristine; ProMECE-CytaBOM, prednisone, cyclophosphamide, etoposide, epidoxorubicin, cytarabine, bleomycin, vincristine, methotrexate with
leucovorin; ProMICE-CytaBOM, prednisone, cyclophosphamide, etoposide, idarubicin, cytarabine, bleomycin, vincristine, methotrexate with leucovorin;
CIOP, cyclophosphamide, idarubicin, vincristine, prednisone; COP or CVP, cyclophosphamide, vincristine, prednisolone (or prednisone); COPE,
cyclophosphamide, vincristine, prednisolone, etoposide; VEPA-B/FEPP-AB/M-FEPA and VEPA-B/FEPP-B/M-FEPA both contain vincristine,
cyclophosphamide, prednisolone, doxorubicin, bleomycin, etoposide, procarbazine, methotrexate, leucovorin, vindesine (at differing doses and schedules of
administration); ACVBP, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone; CNOP, cyclophosphamide, mitoxantrone, vincristine,
prednisone; PAdriaCEBO, prednisolone, adriamycin, cyclophosphamide, etoposide, bleomycin, vincristine; IFN, interferon; GCSF, granulocyte colony
stimulating factor; MTX, methotrexate; PACEBOM, prednisolone, doxorubicin, cyclophosphamide, etoposide, bleomycin, vincristine, methotrexate;
MACOP-B, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin; CAPOMEt, weekly alternating cyclophosphamide and
doxorubicin, vincristine and prednisolone, methotrexate with leucovorin and etoposide; MECOP-B, methotrexate, epirubicin, cyclophosphamide,
vincristine, prednisolone, and bleomycin; B-CHOP-M, bleomycin, cyclophosphamide, doxorubicin, vincristine, prednisolone and methotrexate; PEEC-M,
methylprednisolone, vindesine, etoposide, chlorambucil and methotrexate; CVmP, cyclophosphamide, teniposide, prednisone; CTVmP, cyclophosphamide,
pirarubicin, teniposide, prednisone; ProMACE-MOPP, procarbazine, methotrexate with leucovorin, doxorubicin, cyclophosphamide, and etoposide; m-
BACOD, low-dose methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone; ProMACE-CytaBOM,
prednisone, doxorubicin, cyclophosphamide, and etoposide, followed by cytarabine, bleomycin, vincristine, and methotrexate with leucovorin rescue;
CHVmP-VB, cyclophosphamide, doxorubicin, teniposide, prednisone and vincristine, bleomycin; BACOP, bleomycin, doxorubicin, cyclophosphamide,
vincristine, prednisone; m-BACOD, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, methotrexate with leucovorin; F-MACHOP, 5-
ﬂuorouracil, methotrexate with leucovorin, cytarabine, cyclophosphamide, doxorubicin, vincristine, prednisone; CHVP, cyclophosphamide, doxorubicin,
etoposide, prednisolone; MCP, mitoxantrone; chlorambucil, prednisolone; CID, chlorambucil, idarubicin, dexamethasone; CD, chlorambucil,
dexamethasone; F, ﬂudarabine; CMD, chlorambucil, mitoxantrone, dexamethasone; FMD, ﬂudarabine, mitoxantrone, dexamethasone; COPA,
cyclophosphamide, doxorubicin, vincristine and prednisone every 28 days; PmM, prednimustine, mitoxantrone; BOP, bendamustine, vincristine,
prednisone; FM, ﬂudarabine, mitoxantrone; CHVdP, cyclophosphamide, doxorubicin, vindesine, prednisone; FND, ﬂudarabine, mitoxantrone,
dexamethasone; CHOD, cyclophosphamide, doxorubicin, vincristine, dexamethasone, bleomycin; ESHAP, etoposide, methylprednisolone, cytarabine,
cisplatin; NOPP, mitoxantrone, vincristine, procarbazine, prednisone.
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actual reporting of the published studies. To test for
correlations, a complete set of data for both the candidate
surrogate and true end points is required [14] and only half of
all trials had quantitative estimates for both PFS/EFS and OS.
While hazard ratios would have provided a better comparison
of the overall effect of treatment on survival over time, these
were reported in <20% of all trials. Furthermore, in contrast to
trials of metastatic cancer [3, 7], median time-to-event was
often not reached in trials of primary chemotherapy for NHL
thereby rendering it difﬁcult to evaluate the relationship
between time-to-progression and median OS end points, either
at the trial level as differences between treatment arms or to
determine the correlation between these two end points within
individual treatment arms. Finally, since we only included
RCTs of untreated NHL in this study, estimates of these
relationships are not applicable to RCTs of relapsed or
refractory disease or of maintenance strategies.
In this study, we determined correlations as well as estimated
relationships between different end points in RCTs of untreated
aggressive and indolent NHL. Deﬁnition of these relationships
may improve the design of clinical trials in lymphoma.
Estimates between response and efﬁcacy end points may be
helpful for designing randomized phase III RCTs based on
randomized phase II data. Our ﬁndings suggest that 3-year PFS
may be an appropriate surrogate end point for 5-year OS in
clinical trials of aggressive NHL and provides the preliminary
evidence necessary to further evaluate the strength of this
relationship using a meta-analysis with individualized patient
data. Use of PFS rather than OS would lead to considerable lead
time advantage in the evaluation of clinical trials for aggressive
lymphoma, but acceptance of PFS as a surrogate end point is
required in order to expedite approval of novel agents.
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